Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Korab 20 - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Korab 20

Approved

STANDARD

Korab 20

Kopran Limited🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 69af3ceaa4d6065d
Company: Kopran Limited
Type: Standard

Approval Details

Approval Id: 69af3ceaa4d6065d
Drug Approval Philippines Name: Korab 20
Product Name: Korab 20
Registration Number: DR-XY44991
Brand Name: Korab 20
Generic Name: Rabeprazole Sodium
Dosage Form: Enteric-coated tablet
Dosage Strength: 20 mg
Manufacturer: Kopran Limited
Importer: I.E. Medica, Inc.
Distributor: Jackpharma Inc.
Issuance Date: 26 November 2020
Expiry Date: 12 January 2026
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

69af3ceaa4d6065d

Type

Standard

Back to Philippines FDA Approvals